Multicentre US trials for Healos bone graft:
This article was originally published in Clinica
Swiss company Sulzer Medica has begun a US multicentre clinical trial of Orquest's Healos bone graft substitute used in combination with Sulzer's BAK interbody fusion device, following positive preliminary trial results. Healos, a mineralised collagen product, could eliminate the need to harvest the patient's own bone during spinal surgery, thus reducing hip pain, surgery time and hospital stay. The BAK device is produced by Winterthur-based Sulzer's subsidiary Sulzer Spine-Tech, which holds exclusive worldwide (excluding Japan) marketing rights and distribution rights for Healos. Mountain View, California-based Orquest CE-marked the bone graft last year.